Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M. Aparicio, Christopher J. Logothetis, Xuemei Wang et al.|Clinical Cancer Research|2015Cited by 297
The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC).Ana M. Aparicio, Paul G. Corn, Lianchun Xiao et al.|Journal of Clinical Oncology|2017Cited by 20
A comprehensive molecular characterization of aggressive variant prostate cancer (PC).Ana M. Aparicio, Sankar N. Maity, Li Shen et al.|Journal of Clinical Oncology|2015Cited by 2
Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX).Ana M. Aparicio, Sankar N. Maity, Li Shen et al.|Journal of Clinical Oncology|2015Cited by 1
AVPC Molecular Signature Supplementary Tables 1-10 from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M. Aparicio, Christopher J. Logothetis, Paul G. Corn et al.|Unknown|2023Cited by 0